In July Cellda AB (Cellda) completed a new share issue of approximately SEK 3,7 million. A number of existing shareholders and one new shareholder participated in the share issue. Cellda intends to use the new funding to further develop its software, Cellda® Prostate, for a more effective and consistent diagnosis of prostate cancer benefiting both patients and healthcare providers.